WuXi AppTec (02359) disclosed in a regulatory filing that it executed a significant share repurchase on July 15, 2025. The pharmaceutical leader deployed RMB 20.0034 million to buy back 250,400 of its Shanghai-listed A shares. Transaction records indicate the per-share purchase price fluctuated between RMB 79.01 and RMB 80.76 during the trading session. This strategic move follows the company's ongoing capital allocation program aimed at enhancing shareholder value. Market analysts note such buybacks often signal management's confidence in the firm's intrinsic worth amid current market valuations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。